Real-world effectiveness of osteoporosis treatment in the oldest old
Open Access
- 30 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Osteoporosis International
- Vol. 31 (8), 1525-1533
- https://doi.org/10.1007/s00198-020-05380-6
Abstract
Summary We studied effectiveness of osteoporosis treatment in women older than 80 years, who often are not included in clinical trials. Treatments were as effective on bone density and fractures as in younger women. Introduction To study real-world effectiveness of osteoporosis treatment on BMD and fractures in the oldest old women (≥ 80 years) compared with women (60–79 years) in the clinical setting using Swedish health register data. Methods National registers and data from DXA machines were used to study effectiveness of all available osteoporosis treatments in women 60–79 and ≥ 80 years using three approaches: (1) Total Hip BMD change up to 8 years after treatment start; (2) fracture incidence where patients served as their own controls, comparing the first 3 months after treatment start with the subsequent 12 months; and (3) comparison of fracture incidence post-fracture in women ≥ 80 years treated with osteoporosis treatment or calcium/vitamin D. Results Analysis 1: Total Hip BMD increased by up to 6.7% and 7.7% in women 60–79 and ≥ 80 years old, respectively. The mean increase in BMD was 1.1%-units per year in both age groups. Analysis 2: Relative to the 3-month baseline, fracture incidence decreased during the subsequent 12 months of treatment. Incidence rate ratios were estimated at 0.65, 0.74, 0.29, and 0.81 for any, hip, vertebral, and non-hip-non-vertebral fracture, respectively. Analysis 3: A 24-month incidence of any fracture in women ≥ 80 years given post-fracture osteoporosis treatment was lower (HR = 0.78) than in women given calcium/vitamin D, but treatment allocation was not random, with lower mortality (HR = 0.51) in patients receiving OP treatment. Conclusions Osteoporosis medication in women > 80 years in clinical practice likely works, and the magnitude of effect is similar to what was estimated in younger women. The choice between osteoporosis treatment and calcium/vitamin D after fracture in women ≥ 80 years is not random but appears associated with the patient’s health status and presence of vertebral fractures, rather than the known risk profile of sustaining a fracture at a high age.Keywords
Funding Information
- Amgen Ltd.
This publication has 26 references indexed in Scilit:
- Management of osteoporosis of the oldest oldOsteoporosis International, 2014
- The annual number of hip fractures in Sweden will double from year 2002 to 2050Acta Orthopaedica, 2014
- Trends in Fracture Incidence: A Population-Based Study Over 20 YearsJournal of Bone and Mineral Research, 2013
- Osteoporosis: burden, health care provision and opportunities in the EUArchives of Osteoporosis, 2011
- Longitudinal change in clinical fracture incidence after initiation of bisphosphonatesOsteoporosis International, 2009
- Mortality, Disability, and Nursing Home Use for Persons with and without Hip Fracture: A Population‐Based StudyJournal of the American Geriatrics Society, 2002
- Epidemiology and outcomes of osteoporotic fracturesThe Lancet, 2002
- Long-Term Risk of Osteoporotic Fracture in MalmöOsteoporosis International, 2000
- World-wide Projections for Hip FractureOsteoporosis International, 1997
- Epidemiology of hip fracturesBone, 1996